Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15534350 | 0.92 | PTK2 (0.43) | JAK2JAK1JAK3PTK2PTK2B | |
| SCHEMBL15546845 | 0.84 | JAK3 (0.48) | JAK2JAK1JAK3NTRK1STK17B | |
| SCHEMBL15557248 | 0.83 | JAK3 (0.60) | JAK2JAK1JAK3NTRK1STK17A | |
| SCHEMBL15547643 | 0.81 | JAK2 (0.55) | JAK2JAK1JAK3NTRK1STK17B | |
| SCHEMBL16782550 | 0.78 | JAK3 (0.61) | JAK2JAK1JAK3 | |
| SCHEMBL15546703 | 0.78 | NTRK1 (0.43) | JAK2JAK1JAK3NTRK1PTK2 | |
| SCHEMBL15547065 | 0.76 | JAK2 (0.54) | JAK2JAK1JAK3NTRK1STK17B | |
| SCHEMBL15547004 | 0.76 | JAK3 (0.52) | JAK2JAK1JAK3NTRK1STK17B | |
| SCHEMBL15546960 | 0.75 | JAK3 (0.59) | JAK2JAK1JAK3NTRK1STK17A | |
| SCHEMBL15547305 | 0.75 | JAK2 (0.53) | JAK2JAK1JAK3NTRK1STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | claimed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | claimed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | claimed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | claimed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | claimed |
| EP-2855451-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2015-04-08 | — | — | EP | claimed |
| WO-2013174895-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-11-28 | — | — | WO | claimed |
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| EP-2855451-B1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LTD (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9655897-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2017-05-23 | — | — | US | disclosed |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-9296725-B2 | Heterocyclyl pyrimidine analogues as TYK2 inhibitors | CELLZOME LIMITED (GB) | 2016-03-29 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | CELLZOME LIMITED (GB) | 2015-06-18 | — | — | US | disclosed |
| EP-2855451-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | Cellzome Limited (GB) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013174895-A1 | HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS | CELLZOME LIMITED (GB) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166513-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | JAK2 10/4885JAK1 6/4885JAK3 15/4885 |
| US-20160184307-A1 | Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors | TYK2, TXK, IRAK1 | JAK2 10/4885JAK1 6/4885JAK3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.